Stock EXEL EXELIXIS, INC.
Add to a list

Company Exelixis, Inc.

Equities

EXEL

US30161Q1040

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 02:30:00 13/01/2026 am IST 		5-day change 1st Jan Change
44.06 USD +0.05% Intraday chart for Exelixis, Inc. +3.92% +0.52%
10:50am Exelixis, Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 05:15 PM
12/01 Independence, Under Review Zonebourse

Business description: Exelixis, Inc.

Exelixis, Inc. is an oncology company. The Company is engaged in developing medicines and combination regimens at the forefront of cancer care. It has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma (RCC), for previously treated hepatocellular carcinoma (HCC) and for previously treated, radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC), and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer (MTC). The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor (MR) approved the treatment of hypertension.

Number of employees: 1,147

Sales by Activity: Exelixis, Inc.

Fiscal Period: December20202021202220232024

Biotechnology

99Cr 143.5Cr 161.11Cr 183.02Cr 216.87Cr
See all business segments

Geographical breakdown of sales: Exelixis, Inc.

Fiscal Period: December20202021202220232024

United States (U.S.)

75Cr 108.94Cr 141.37Cr 164.57Cr 182.3Cr

Europe

15Cr 30Cr 17Cr 14Cr 32Cr

Japan

8.3Cr 4.35Cr 2.87Cr 3.95Cr 2.71Cr
See all geographic segments

Executive Committee: Exelixis, Inc.

Manager TitleAgeSince
Michael Morrissey CEO
 Chief Executive Officer 65 22/07/2010
Christopher Senner DFI
 Director of Finance/CFO 58 15/07/2015
Dana Aftab COO
 Chief Operating Officer 63 01/02/2016
Susan T. Hubbard IRC
 Investor Relations Contact - 01/12/2016
Brenda Hefti LAW
 General Counsel - 07/11/2025
See EXELIXIS, INC. governance

Composition of the Board of Directors: Exelixis, Inc.

Director TitleAgeSince
Jack Wyszomierski BRD
 Director/Board Member 69 01/02/2004
George Poste BRD
 Director/Board Member 82 01/08/2004
Stelios Papadopoulos CHM
 Chairman 77 01/01/1998
Michael Morrissey BRD
 Director/Board Member 65 22/07/2010
Julie Smith BRD
 Director/Board Member 55 22/09/2016
Maria Freire BRD
 Director/Board Member 71 05/04/2018
Tomas Jan Heyman BRD
 Director/Board Member 70 31/05/2023
David Johnson BRD
 Director/Board Member 43 31/05/2023
Robert Oliver BRD
 Director/Board Member 67 31/05/2023
Mary Beckerle BRD
 Director/Board Member 71 05/01/2024
Composition of the Board of Directors

Shareholders: Exelixis, Inc.

NameEquities%Valuation
BlackRock Advisors LLC
10.14 %
2,71,85,260 10.14 % 1 192 M $
Vanguard Fiduciary Trust Co.
9.722 %
2,60,64,571 9.722 % 1 142 M $
Farallon Capital Management LLC
7.274 %
1,95,01,500 7.274 % 855 M $
Farallon Capital Management LLC
5.859 %
1,57,09,500 5.859 % 689 M $
Renaissance Technologies LLC
5.766 %
1,54,59,266 5.766 % 678 M $
List of EXELIXIS, INC. shareholders

Company details: Exelixis, Inc.

Exelixis, Inc.

1851 Harbor Bay Parkway

94502, Alameda

+650 837 7000

http://www.exelixis.com
address Exelixis, Inc.(EXEL)

Bio Therapeutic Drugs

Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5d. change 1-year change 3-years change Capi.($)
EXELIXIS, INC. Stock Exelixis, Inc.
+0.05%+3.92%+22.32%+163.99% 1.19TCr
ARGENX SE Stock argenx SE
-3.14%-1.73%+3.87%+82.75% 4.8TCr
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-0.40%+4.35%+84.93%+8.53% 4.2TCr
INSMED INCORPORATED Stock Insmed Incorporated
-4.69%-4.27%+157.04%+768.57% 3.58TCr
BIONTECH SE Stock BioNTech SE
+2.33%+5.50%-16.83%-31.61% 2.56TCr
GENMAB A/S Stock Genmab A/S
-0.92%+7.56%+38.32%-21.04% 2.08TCr
WUXI BIOLOGICS (CAYMAN) INC. Stock WuXi Biologics (Cayman) Inc.
+5.80%+18.20%+134.44%-41.95% 1.99TCr
SUMMIT THERAPEUTICS INC. Stock Summit Therapeutics Inc.
-13.41%-2.29%-4.54%+323.88% 1.31TCr
AKESO, INC. Stock Akeso, Inc.
-4.60%+2.73%+117.15%+161.81% 1.49TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. Stock Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
-2.70%+10.37%+183.30% - 1.46TCr
Average -0.89%+4.42%+72.00%+157.21% 2.47TCr
Weighted average by Cap. -1.39%+2.97%+69.10%+165.28%
See all sector performances

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings

Trader

Trader

This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Investor

Investor

This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.

Global

Global

This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

Quality

Quality

This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.

ESG MSCI
BB
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
44.06USD
Average target price
45.50USD
Spread / Average Target
+3.27%
Consensus
EPS Estimates
Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Income Statement and Estimates

More financial data
  1. Stock Market
  2. Equities
  3. EXEL Stock
  4. Company Exelixis, Inc.

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States
United-States
Canada
Canada

MIDDLE EAST

Saudi Arabia
Saudi Arabia
United Arab Emirates
United Arab Emirates

EUROPE

France
France
Deutschland
Deutschland
Suisse
Suisse
Schweiz
Schweiz
Italia
Italia
Österreich
Österreich
België
België
Nederland
Nederland
España
España
Sverige
Sverige
United Kingdom
United Kingdom

APAC

Australia
Australia
India
India
Hong Kong
Hong Kong
United States

MarketScreener is also available in this country: United States.

Switch edition
Stay in the current country edition